Arpida re-aligns activities to support transition of its research portfolio
Arpida's research operations, including rational drug design and chemistry, will continue at its corporate headquarters in Reinach, Switzerland. This strategic re-alignment shall bring about the appropriate concentration, integration and re-focusing of resources required for an efficient transition of the most advanced research compounds into development.
In financial terms, the refocusing operation will lead to a non-cash impairment of tangible and intangible assets of approximately CHF 1.2 million and CHF 6.1 million, respectively. These charges will be included in the 2006 accounts. The operation is expected to be completed in the second quarter of 2007.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.